EMBL-EBI | Chemical Biology | ChEBI
Example searches: iron*, InChI=1S/CH4O/c1-2/h2H,1H3, caffeine | Advanced Search
CHEBI:29608 - isoformononetin
| Formula | C16H12O4 |
| Net Charge | 0 |
| Average Mass | 268.268 |
| Monoisotopic Mass | 268.07356 |
| SMILES | COc1ccc2c(=O)c(-c3ccc(O)cc3)coc2c1 |
| InChI | InChI=1S/C16H12O4/c1-19-12-6-7-13-15(8-12)20-9-14(16(13)18)10-2-4-11(17)5-3-10/h2-9,17H,1H3 |
| InChIKey | LNIQZRIHAMVRJA-UHFFFAOYSA-N |
| Roles Classification |
|---|
| Biological Roles: | metabolite Any intermediate or product resulting from metabolism. The term 'metabolite' subsumes the classes commonly known as primary and secondary metabolites. apoptosis inhibitor Any substance that inhibits the process of apoptosis (programmed cell death) in multi-celled organisms. |
| Application: | bone density conservation agent An agent that inhibits bone resorption and/or favor bone mineralization and bone regeneration. Used to heal bone fractures and to treat bone diseases such as osteopenia and osteoporosis. |
| ChEBI Ontology |
|---|
| Outgoing Relation(s) |
| isoformononetin (CHEBI:29608) has functional parent daidzein (CHEBI:28197) |
| isoformononetin (CHEBI:29608) has role apoptosis inhibitor (CHEBI:68494) |
| isoformononetin (CHEBI:29608) has role bone density conservation agent (CHEBI:50646) |
| isoformononetin (CHEBI:29608) has role metabolite (CHEBI:25212) |
| isoformononetin (CHEBI:29608) is a 7-methoxyisoflavones (CHEBI:140356) |
| isoformononetin (CHEBI:29608) is a hydroxyisoflavone (CHEBI:38755) |
| IUPAC Name |
|---|
| 3-(4-hydroxyphenyl)-7-methoxy-4H-chromen-4-one |
| Synonyms | Source |
|---|---|
| 4'-Hydroxy-7-methoxyisoflavone | HMDB |
| 7-O-methyldaidzein | ChEBI |
| 4'-Hydroxy-7-methoxyisoflavone | KEGG COMPOUND |
| Manual Xrefs | Databases |
|---|---|
| C12125 | KEGG COMPOUND |
| HMO | PDBeChem |
| DB04202 | DrugBank |
| LMPK12050039 | LIPID MAPS |
| HMDB0033994 | HMDB |
| CPD-3343 | MetaCyc |
| C00009382 | KNApSAcK |
| Registry Numbers | Sources |
|---|---|
| Reaxys:251318 | Reaxys |
| CAS:486-63-5 | HMDB |
| Citations |
|---|